Abstract
Ebola virus (EBOV) is a highly pathogenic virus causing severe hemorrhagic fever with a high case fatality rate of 50% - 90% in humans. Without an approved vaccine or treatments, Ebola outbreak management has been limited to palliative care and barrier methods to prevent transmission. These approaches, however, have yet to end the 2014 outbreak of Ebola after its prolonged presence in West Africa. As with the increase of outbreaks, a significant effort has been made to develop promising countermeasures for the prevention and treatment of Ebola virus infection. In this review, development of therapeutics and potential inhibitors for Ebola virus infection will be discussed.
Keywords: Ebola virus, Therapeutics, Small molecules, Vaccines and antibody.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:The Drug Targets and Antiviral Molecules for Treatment of Ebola Virus Infection
Volume: 17 Issue: 3
Author(s): Wenjiao Wu and Shuwen Liu
Affiliation:
Keywords: Ebola virus, Therapeutics, Small molecules, Vaccines and antibody.
Abstract: Ebola virus (EBOV) is a highly pathogenic virus causing severe hemorrhagic fever with a high case fatality rate of 50% - 90% in humans. Without an approved vaccine or treatments, Ebola outbreak management has been limited to palliative care and barrier methods to prevent transmission. These approaches, however, have yet to end the 2014 outbreak of Ebola after its prolonged presence in West Africa. As with the increase of outbreaks, a significant effort has been made to develop promising countermeasures for the prevention and treatment of Ebola virus infection. In this review, development of therapeutics and potential inhibitors for Ebola virus infection will be discussed.
Export Options
About this article
Cite this article as:
Wu Wenjiao and Liu Shuwen, The Drug Targets and Antiviral Molecules for Treatment of Ebola Virus Infection, Current Topics in Medicinal Chemistry 2017; 17 (3) . https://dx.doi.org/10.2174/1568026616666160829161318
DOI https://dx.doi.org/10.2174/1568026616666160829161318 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cytostatic Properties of Some Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type I Receptor Antagonists
Current Pharmaceutical Design Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Bioactive Albumin-Based Carriers for Tumour Chemotherapy
Current Cancer Drug Targets Radiation Therapy in the Early 21st Century: Technological Advances
Current Cancer Therapy Reviews Low Molecular Weight and Oligomeric Chitosans and Their Bioactivities
Current Topics in Medicinal Chemistry The Radio-Sensitizing Effect of Pharmacological Concentration of Ascorbic Acid on Human Pancreatic Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Hypoxia-inducible Factor (HIF) in Hormone Signaling During Health and Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry The Caveolin-1 Connection to Cell Death and Survival
Current Molecular Medicine Neuroprotective Effects of Non-Classical Estrogen-Like Signaling Activators: from Mechanism to Potential Implications
CNS & Neurological Disorders - Drug Targets T Cell Replicative Senescence in Human Aging
Current Pharmaceutical Design ACE2/Angiotensin-(1-7)/Mas Receptor Axis in Human Cancer: Potential Role for Pediatric Tumors
Current Drug Targets Gamma-Secretase as a Pharmacological Target in Alzheimer Disease Research: When, Why and How?
Current Pharmaceutical Design Polyisoprenylated Cysteinyl Amide Inhibitors: A Novel Approach to Controlling Cancers with Hyperactive Growth Signaling
Current Medicinal Chemistry Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective
Current Pharmaceutical Design Polypharmacology of Approved Anticancer Drugs
Current Drug Targets Ansamycin Inhibitors of Hsp90: Natures Prototype for Anti-Chaperone Therapy
Current Topics in Medicinal Chemistry Titanocene Y - Transport and Targeting of an Anticancer Drug Candidate
Letters in Drug Design & Discovery Efficacy and Safety of the Combination of Docetaxel (Taxotere®) with Targeted Therapies in the Treatment of Solid Malignancies
Current Drug Targets Patented Biomarkers for the Early Detection of Ovarian Cancer
Recent Patents on Biomarkers New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets